Enochian gets license for inhaled treatment tech

By The Science Advisory Board staff writers

June 21, 2021 -- Enochian BioSciences has acquired a license for technology that can potentially treat and prevent all variants of the coronavirus as well as influenza.

Developed by Dr. Serhat Gumrukçu, PhD, director of Seraph Research Institute, the inhaled drug tricks the viruses to trigger the cells they infect to commit suicide instead of becoming virus-making factories. Delivered via a nanoparticle, the drug either rapidly treats an infection or waits for a cell to become infected before attacking it. It's possible a single inhalation of the drug could both treat and protect against infection for relatively long periods of time, according to Enochian.

The firm is requesting a preinvestigational new drug meeting with the U.S. Food and Drug Administration (FDA) soon.

Financial details of the license were not disclosed.

Copyright © 2021 scienceboard.net

BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter